Look for M&A activity in biotech, says Kevin Mahn

Kevin Mahn, CIO at Hennion & Walsh Asset Management and SmartTrust® Portfolio Manager tells Reuters’ Fred Katayama biotech firms with drugs already in the pipeline are prime acquisition targets for big drug makers. with

Click here to watch the complete discussion on Reuters.